Black Diamond Therapeutics Announces Financial Results and Strategic Updates for Q1 2025

May 12, 2025 - 22:08

In a recent corporate update, Black Diamond Therapeutics revealed significant advancements in its clinical trials and financial standing for the first quarter of 2025. The company is on track to present clinical data from its Phase 2 trial of BDTX-1535, targeting first-line patients with non-classical EGFR mutations in non-small cell lung cancer (NSCLC), with results expected in the fourth quarter of 2025.

Additionally, the company has initiated an expansion of its investigator-sponsored Phase 0/1 trial, focusing on newly diagnosed glioblastoma patients with EGFR alterations. This expansion commenced in the first quarter of 2025, reflecting the company’s commitment to exploring innovative treatment options for challenging cancers.

Financially, Black Diamond Therapeutics reported cash, cash equivalents, and investments totaling $152.4 million as of March 31, 2025. This financial position is anticipated to adequately support the company’s operations through to the fourth quarter of 2027, ensuring continued progress in its clinical and research endeavors.